Nelde, Alexander http://orcid.org/0000-0002-1248-8504
Klammer, Markus G. http://orcid.org/0000-0002-8990-262X
Nolte, Christian H. http://orcid.org/0000-0001-5577-1775
Stengl, Helena http://orcid.org/0000-0002-9270-7665
Krämer, Michael http://orcid.org/0000-0002-0310-5903
von Rennenberg, Regina http://orcid.org/0000-0003-3444-2045
Meisel, Andreas
Scheibe, Franziska
Endres, Matthias http://orcid.org/0000-0001-6520-3720
Scheitz, Jan F. http://orcid.org/0000-0001-5835-4627
Meisel, Christian http://orcid.org/0000-0003-2984-5480
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 6 February 2023
Revised: 6 April 2023
Accepted: 7 April 2023
First Online: 20 April 2023
Declarations
:
: CM is part of patent applications to detect and predict clinical outcomes and to manage, diagnose, and treat neurological conditions, all of which are outside the submitted work. CHN received research grants from German Ministry of Research and Education, German Center for Neurodegenerative Diseases, German Center for cardiovascular Research, and speaker and/or consultation fees from Abbott, Alexion, Astra Zeneca, Bayer Pharma, Bristol-Myers Squibb, Daiichi Sankyo, Novartis, Pfizer Pharma, Portola and Takeda all outside the submitted work. ME reports grants from Bayer and fees paid to the Charité from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, GSK, Sanofi, Covidien, Novartis, Pfizer, all outside the submitted work. The remaining authors have no conflicts of interest or competing interests to declare.
: Ethics approval for this study was obtained from the Institutional Review Board of the Charité Universitätsmedizin Berlin. The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki.